1. Israel Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Tikun Olam-Cannbit Pharmaceuticals Ltd.

Tikun Olam-Cannbit Pharmaceuticals Ltd.

TKUN.TA
Tikun Olam-Cannbit Pharmaceuticals Ltd.IL flagTel Aviv Stock Exchange
485.60
ILA
-68.40
- -
4.13MMarket Cap
Tikun Olam-Cannbit Pharmaceuticals Ltd.
TKUN.TA
(Tel Aviv Stock Exchange)

Recent

price

485.60

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
59.47
88.14
97.05
70.18
41.75
- -
- -
Revenue per Share
19,207.23
-17,806.71
-11,711.03
-3,749.77
-2,496.91
-796.12
-1.46
-279.89
-55.74
-90.46
-77.72
-94.96
-141.05
-47.9
- -
-31.58
Basic EPS, GAAP
-2,680.78
-2,592.23
-2,121.72
-1,798.17
-2,148.28
-469.55
-0.93
-46.07
-83.47
-139.21
-79.7
-59.31
-6.54
-4.52
- -
-18.62
Free Cash Flow per Basic Share
23,809.52
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
-14,203
-25,802.1
-30,659.36
-32,127.98
-32,924.1
-1.37
-279.97
-164.63
-178.77
-232.67
-287.41
-372.71
-328.42
- -
-1,305.9
Book Value per Share
- -
22,520.74
9,668.13
7,273.97
4,541.92
3,745.81
2.99
1.43
121.11
175.9
180.95
156.9
23.33
-18.1
- -
148.57
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
1
- -
- -
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
22
37
49
44
35
9
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
-147.66
-113.94
-54.1
-64.38
-41.97
-105.36
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
14
20
52
59
30
12
- -
Depreciation Expense
22
-20
-13
-4
-3
-1
- -
-21
-11
-33
-33
-48
-89
-40
-16
-1
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
-152.1
-88.17
-97.85
-200.97
-114.73
-174.17
- -
Profit Margin (%)
- -
6
5
3
- -
-1
1
1
-8
15
20
16
-4
-13
-20
-1
Working Capital
- -
- -
- -
- -
- -
- -
1
4
8
7
8
8
6
5
2
- -
LT Debt
- -
26
11
8
5
4
- -
- -
100
136
144
117
33
-5
-21
4
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
4.39
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'16
Sep'16
Dec'16
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
- -
- -
Market Capitalization
16,943
16,840
12,701

Working Capital

FRC

•

in mil. unless spec.
Jun'16
Sep'16
Dec'16
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
1
1
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9,234.01%
18.22%
292.02%
Free Cash Flow
564.16%
-58.34%
-153.16%
Net Income, GAAP
2,174.02%
3.16%
-60.47%
Sales/Revenue/Turnover
- -
-0.22%
-73.96%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
44
2024
- -
- -
- -
- -
35
2025
- -
- -
- -
- -
9

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-141.05
2024
- -
- -
- -
- -
-47.9
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Vencanna Ventures Inc. (VENI.CN)
Granules India Limited (GRANULES.NS)
South American Gold Corp. (SAGD)
4Front Ventures Corp. (FFVWF)
Stemsation International, Inc. (STSN)
West Island Brands Inc. (WIB.CN)
Business
Tikun Olam-Cannbit Pharmaceuticals Ltd is a pharmaceutical company specializing in the research, development, cultivation, production, marketing, storage, distribution, export, and sale of cannabis-based medical products. The company provides a broad portfolio of medical cannabis products targeting relief and treatment across numerous medical indications such as cancer, PTSD, epilepsy, Crohn's disease, multiple sclerosis, cerebral palsy, and chronic pain. Core offerings include proprietary cannabis strains developed through extensive genetic R&D, advanced cultivation methods yielding approximately 9 tonnes annually, and innovative dosing techniques supported by over 35 clinical and preclinical studies. Tikun Olam-Cannbit also offers patient training, counseling, and care services through its integrated ecosystem that spans from cultivation farms to direct delivery with personalized treatment regimens. The company operates primarily in Israel, with a production facility in the northern region and cultivation farms near the Dead Sea, and serves global markets including Europe, benefiting from recent EU-GMP certification that facilitates production and export of medical cannabis products internationally. Founded in 2006 and headquartered in Nof HaGalil, Israel, Tikun Olam was acquired by Cannbit Pharmaceuticals in 2019, expanding its operational and research capabilities. Recent major developments include securing EU-GMP certification in 2025 to advance international market expansion, establishing strategic partnerships such as the supply agreement with SciSparc for CBD-rich oil use in neurological treatments, and ongoing clinical trials supporting novel product innovations and formulations. The company is positioned to grow within key markets including Israel, the US, and Europe, leveraging its legacy of scientific research, robust clinical data, and integrated care approach to meet evolving medical cannabis demands worldwide. Tikun Olam-Cannbit Pharmaceuticals Ltd remains focused on sustainable growth through global production agreements and the continuous enhancement of products aimed at improving patients’ quality of life using clinically supported cannabis therapies.